<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="0" ids="31941">Oxaliplatin</z:chebi> is an important drug used in the treatment of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, it frequently causes severe <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0009830'>peripheral neuropathies</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We recently reported that repeated administration of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> induced cold <z:mp ids='MP_0005407'>hyperalgesia</z:mp> in the early phase and mechanical <z:mp ids='MP_0003177'>allodynia</z:mp> in the late phase in rats, and that oxalate derived from <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> is involved in the cold <z:mp ids='MP_0005407'>hyperalgesia</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>In the present study, we examined the effects of Ca²⁺ channel blockers on <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-induced cold <z:mp ids='MP_0005407'>hyperalgesia</z:mp> in rats </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Cold <z:mp ids='MP_0005407'>hyperalgesia</z:mp> was assessed by the <z:chebi fb="15" ids="15347">acetone</z:chebi> test </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="31941">Oxaliplatin</z:chebi> (4 mg/kg), <z:chebi fb="199" ids="26708">sodium</z:chebi> oxalate (1.3 mg/kg) or vehicle was injected i.p. on days 1 and 2 </plain></SENT>
<SENT sid="6" pm="."><plain>Ca²⁺ (diltiazem, <z:chebi fb="1" ids="7565">nifedipine</z:chebi> and ethosuximide) and Na⁺ (mexiletine) channel blockers were administered p.o. simultaneously with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> or oxalate on days 1 and 2 </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: <z:chebi fb="0" ids="31941">Oxaliplatin</z:chebi> (4 mg/kg) induced cold <z:mp ids='MP_0005407'>hyperalgesia</z:mp> and increased in the transient receptor potential melastatin 8 (TRPM8) <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels in the dorsal root ganglia (DRG) </plain></SENT>
<SENT sid="8" pm="."><plain>Furthermore, oxalate (1.3 mg/kg) significantly induced the increase in TRPM8 protein in the DRG </plain></SENT>
<SENT sid="9" pm="."><plain>Treatment with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> and oxalate (500 μM for each) also increased the TRPM8 <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels and induced Ca²⁺ influx and nuclear factor of activated T-cell (NFAT) nuclear translocation in cultured DRG cells </plain></SENT>
<SENT sid="10" pm="."><plain>These changes induced by oxalate were inhibited by <z:chebi fb="1" ids="7565">nifedipine</z:chebi>, diltiazem and mexiletine </plain></SENT>
<SENT sid="11" pm="."><plain>Interestingly, co-administration with <z:chebi fb="1" ids="7565">nifedipine</z:chebi>, diltiazem or mexiletine prevented the <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-induced cold <z:mp ids='MP_0005407'>hyperalgesia</z:mp> and increase in the TRPM8 <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels in the DRG </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: These data suggest that the L type Ca²⁺ channels/NFAT/TRPM8 pathway is a downstream mediator for <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-induced cold <z:mp ids='MP_0005407'>hyperalgesia</z:mp>, and that Ca²⁺ channel blockers have prophylactic potential for <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> </plain></SENT>
</text></document>